Growth Metrics

Castle Biosciences (CSTL) Current Deferred Revenue (2020 - 2021)

Castle Biosciences' Current Deferred Revenue history spans 2 years, with the latest figure at $3.0 million for Q3 2021.

  • For Q3 2021, Current Deferred Revenue fell 64.08% year-over-year to $3.0 million; the TTM value through Sep 2021 reached $3.0 million, down 64.08%, while the annual FY2020 figure was $6.6 million, N/A changed from the prior year.
  • Current Deferred Revenue for Q3 2021 was $3.0 million at Castle Biosciences, down from $6.2 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $8.4 million in Q2 2020 and bottomed at $3.0 million in Q3 2021.